| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contrast Media | 31 | 2025 | 479 | 5.610 |
Why?
|
| Nanoparticles | 20 | 2025 | 232 | 3.900 |
Why?
|
| Liposomes | 30 | 2019 | 188 | 2.910 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2025 | 3560 | 2.280 |
Why?
|
| Placenta | 6 | 2025 | 508 | 1.940 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2025 | 2093 | 1.920 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2022 | 137 | 1.570 |
Why?
|
| Drug Carriers | 12 | 2012 | 100 | 1.370 |
Why?
|
| Gadolinium | 7 | 2019 | 107 | 1.350 |
Why?
|
| Optical Imaging | 3 | 2018 | 67 | 1.260 |
Why?
|
| Indocyanine Green | 3 | 2023 | 55 | 1.200 |
Why?
|
| Fluorocarbons | 2 | 2018 | 56 | 1.150 |
Why?
|
| Alzheimer Disease | 6 | 2024 | 799 | 1.130 |
Why?
|
| Computer-Aided Design | 2 | 2020 | 21 | 1.130 |
Why?
|
| Models, Anatomic | 2 | 2020 | 99 | 1.060 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2021 | 372 | 1.050 |
Why?
|
| Drug Delivery Systems | 7 | 2012 | 186 | 1.030 |
Why?
|
| Triiodobenzoic Acids | 5 | 2021 | 31 | 1.020 |
Why?
|
| Ferrosoferric Oxide | 1 | 2025 | 25 | 0.920 |
Why?
|
| Phantoms, Imaging | 4 | 2018 | 134 | 0.850 |
Why?
|
| Animals | 51 | 2025 | 34235 | 0.840 |
Why?
|
| Placenta Accreta | 1 | 2025 | 157 | 0.780 |
Why?
|
| X-Ray Microtomography | 3 | 2021 | 85 | 0.770 |
Why?
|
| Mice | 29 | 2025 | 17645 | 0.760 |
Why?
|
| Plaque, Amyloid | 3 | 2020 | 64 | 0.760 |
Why?
|
| Angiography | 2 | 2021 | 215 | 0.760 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2018 | 57 | 0.730 |
Why?
|
| Cerebrovascular Disorders | 1 | 2021 | 122 | 0.700 |
Why?
|
| Atherosclerosis | 2 | 2022 | 920 | 0.680 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 69 | 0.650 |
Why?
|
| Medical Oncology | 2 | 2023 | 214 | 0.650 |
Why?
|
| Computer Simulation | 2 | 2021 | 649 | 0.640 |
Why?
|
| Insulin | 3 | 2012 | 1204 | 0.630 |
Why?
|
| Fluorine | 1 | 2018 | 15 | 0.620 |
Why?
|
| Disease Models, Animal | 14 | 2022 | 4396 | 0.610 |
Why?
|
| Amyloid | 2 | 2020 | 65 | 0.610 |
Why?
|
| Hindlimb | 1 | 2018 | 80 | 0.600 |
Why?
|
| Fluorine-19 Magnetic Resonance Imaging | 1 | 2018 | 4 | 0.590 |
Why?
|
| Ethers | 1 | 2018 | 7 | 0.590 |
Why?
|
| Neoplasms | 7 | 2023 | 2780 | 0.590 |
Why?
|
| Integrin alpha4beta1 | 1 | 2018 | 37 | 0.580 |
Why?
|
| Radiography, Thoracic | 3 | 2015 | 148 | 0.560 |
Why?
|
| Aortography | 2 | 2021 | 202 | 0.560 |
Why?
|
| Immunotherapy | 3 | 2023 | 675 | 0.550 |
Why?
|
| Skull | 1 | 2018 | 141 | 0.550 |
Why?
|
| Amyloid beta-Protein Precursor | 3 | 2020 | 126 | 0.530 |
Why?
|
| Blood-Brain Barrier | 2 | 2014 | 143 | 0.520 |
Why?
|
| Neuroblastoma | 2 | 2021 | 505 | 0.510 |
Why?
|
| Pulmonary Blastoma | 1 | 2015 | 11 | 0.480 |
Why?
|
| Aorta | 3 | 2021 | 547 | 0.470 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2014 | 13 | 0.460 |
Why?
|
| Ribonuclease III | 1 | 2015 | 89 | 0.460 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2011 | 246 | 0.460 |
Why?
|
| Presenilin-1 | 2 | 2020 | 53 | 0.450 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 121 | 0.450 |
Why?
|
| Lung | 4 | 2007 | 1496 | 0.450 |
Why?
|
| Computer Peripherals | 1 | 2013 | 4 | 0.440 |
Why?
|
| Cerebral Arteries | 1 | 2014 | 82 | 0.440 |
Why?
|
| Stroke | 1 | 2021 | 986 | 0.420 |
Why?
|
| Nanostructures | 4 | 2008 | 50 | 0.420 |
Why?
|
| Vascular Diseases | 1 | 2015 | 168 | 0.410 |
Why?
|
| Musculoskeletal Diseases | 1 | 2013 | 57 | 0.410 |
Why?
|
| Chest Pain | 1 | 2013 | 125 | 0.400 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 221 | 0.390 |
Why?
|
| Nanomedicine | 1 | 2012 | 14 | 0.390 |
Why?
|
| Mice, Knockout | 4 | 2025 | 3742 | 0.380 |
Why?
|
| Delayed-Action Preparations | 3 | 2007 | 110 | 0.380 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 462 | 0.380 |
Why?
|
| Boronic Acids | 1 | 2012 | 47 | 0.380 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 277 | 0.370 |
Why?
|
| Coronary Angiography | 1 | 2013 | 444 | 0.360 |
Why?
|
| Pediatrics | 1 | 2020 | 1144 | 0.360 |
Why?
|
| Amyloid beta-Peptides | 1 | 2012 | 212 | 0.360 |
Why?
|
| Mice, Transgenic | 6 | 2022 | 2397 | 0.350 |
Why?
|
| Neuroimaging | 3 | 2021 | 339 | 0.350 |
Why?
|
| Humans | 42 | 2025 | 124705 | 0.350 |
Why?
|
| Health Care Costs | 1 | 2013 | 369 | 0.350 |
Why?
|
| Aortic Diseases | 1 | 2013 | 200 | 0.350 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 556 | 0.340 |
Why?
|
| Models, Biological | 4 | 2011 | 1460 | 0.340 |
Why?
|
| Rats | 13 | 2020 | 3728 | 0.330 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 1660 | 0.330 |
Why?
|
| Brain | 4 | 2024 | 2996 | 0.330 |
Why?
|
| Polyethylene Glycols | 6 | 2012 | 227 | 0.320 |
Why?
|
| Female | 23 | 2025 | 66577 | 0.300 |
Why?
|
| Particle Size | 6 | 2009 | 124 | 0.290 |
Why?
|
| Administration, Inhalation | 5 | 2007 | 180 | 0.280 |
Why?
|
| Iohexol | 2 | 2007 | 21 | 0.280 |
Why?
|
| Aerosols | 2 | 2007 | 65 | 0.270 |
Why?
|
| Pregnancy | 6 | 2025 | 7171 | 0.270 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2022 | 172 | 0.270 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 66 | 0.260 |
Why?
|
| Glucose | 2 | 2012 | 879 | 0.260 |
Why?
|
| Mice, Nude | 4 | 2018 | 709 | 0.260 |
Why?
|
| Cardiology | 1 | 2012 | 504 | 0.260 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2017 | 1243 | 0.260 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1059 | 0.250 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 470 | 0.250 |
Why?
|
| Ligands | 4 | 2021 | 539 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3154 | 0.230 |
Why?
|
| Microspheres | 1 | 2003 | 70 | 0.220 |
Why?
|
| Child | 12 | 2023 | 24173 | 0.220 |
Why?
|
| Tumor Burden | 4 | 2021 | 231 | 0.220 |
Why?
|
| Folic Acid | 2 | 2006 | 294 | 0.220 |
Why?
|
| Mouth Neoplasms | 2 | 2023 | 84 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2019 | 584 | 0.210 |
Why?
|
| Tomography, Spiral Computed | 1 | 2003 | 16 | 0.210 |
Why?
|
| Rheology | 1 | 2003 | 33 | 0.210 |
Why?
|
| Carrier Proteins | 2 | 2005 | 1024 | 0.200 |
Why?
|
| Bronchi | 1 | 2003 | 97 | 0.200 |
Why?
|
| Antineoplastic Agents | 5 | 2011 | 1695 | 0.200 |
Why?
|
| Vimentin | 1 | 2022 | 66 | 0.190 |
Why?
|
| Adventitia | 1 | 2022 | 6 | 0.190 |
Why?
|
| Image Enhancement | 3 | 2008 | 163 | 0.190 |
Why?
|
| Protein Binding | 2 | 2018 | 1752 | 0.180 |
Why?
|
| Trachea | 1 | 2003 | 202 | 0.180 |
Why?
|
| Indans | 1 | 2021 | 55 | 0.180 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 1492 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 4406 | 0.180 |
Why?
|
| Male | 17 | 2022 | 61317 | 0.180 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2023 | 144 | 0.180 |
Why?
|
| Moyamoya Disease | 1 | 2021 | 38 | 0.180 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 209 | 0.180 |
Why?
|
| Disposable Equipment | 1 | 2020 | 17 | 0.180 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 581 | 0.170 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 3344 | 0.170 |
Why?
|
| alpha-Synuclein | 1 | 2021 | 122 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 238 | 0.170 |
Why?
|
| Nanotechnology | 3 | 2009 | 48 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 79 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 95 | 0.170 |
Why?
|
| Appendicitis | 1 | 2021 | 127 | 0.170 |
Why?
|
| Finger Phalanges | 1 | 2019 | 3 | 0.170 |
Why?
|
| Age Determination by Skeleton | 1 | 2019 | 9 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 163 | 0.170 |
Why?
|
| tau Proteins | 1 | 2022 | 206 | 0.170 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 49 | 0.170 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2161 | 0.160 |
Why?
|
| Aortic Rupture | 1 | 2021 | 121 | 0.160 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 199 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 1958 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 1695 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 294 | 0.160 |
Why?
|
| Binding, Competitive | 2 | 2012 | 192 | 0.160 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2018 | 41 | 0.150 |
Why?
|
| Placentation | 1 | 2019 | 55 | 0.150 |
Why?
|
| Limit of Detection | 1 | 2018 | 63 | 0.150 |
Why?
|
| Iodine | 2 | 2016 | 23 | 0.150 |
Why?
|
| Solubility | 1 | 2018 | 138 | 0.150 |
Why?
|
| Disease Progression | 2 | 2021 | 2057 | 0.150 |
Why?
|
| Adult | 5 | 2025 | 29554 | 0.150 |
Why?
|
| Child Abuse | 1 | 2021 | 195 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 504 | 0.150 |
Why?
|
| Molecular Conformation | 1 | 2018 | 105 | 0.150 |
Why?
|
| Aortic Aneurysm | 1 | 2021 | 237 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2021 | 296 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 673 | 0.140 |
Why?
|
| Chickens | 1 | 2017 | 636 | 0.140 |
Why?
|
| Membranes, Artificial | 1 | 2017 | 27 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 1396 | 0.140 |
Why?
|
| Chitosan | 1 | 2017 | 20 | 0.140 |
Why?
|
| Models, Animal | 1 | 2019 | 465 | 0.130 |
Why?
|
| Molecular Structure | 2 | 2021 | 295 | 0.130 |
Why?
|
| Doxorubicin | 3 | 2009 | 290 | 0.130 |
Why?
|
| Materials Testing | 1 | 2017 | 73 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2022 | 356 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2022 | 370 | 0.130 |
Why?
|
| Gadolinium DTPA | 2 | 2007 | 47 | 0.130 |
Why?
|
| Cattle | 1 | 2017 | 568 | 0.130 |
Why?
|
| Infant | 4 | 2021 | 12384 | 0.130 |
Why?
|
| Echo-Planar Imaging | 1 | 2016 | 21 | 0.130 |
Why?
|
| Heterografts | 1 | 2016 | 172 | 0.130 |
Why?
|
| Hydrogels | 1 | 2017 | 84 | 0.130 |
Why?
|
| Pericardium | 1 | 2017 | 83 | 0.130 |
Why?
|
| Rabbits | 3 | 2007 | 717 | 0.130 |
Why?
|
| Child, Preschool | 4 | 2021 | 13882 | 0.130 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 2043 | 0.130 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 115 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2007 | 163 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 979 | 0.120 |
Why?
|
| Time Factors | 6 | 2022 | 6323 | 0.120 |
Why?
|
| Organometallic Compounds | 2 | 2016 | 108 | 0.120 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2015 | 3 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2015 | 52 | 0.120 |
Why?
|
| Retinal Dehydrogenase | 1 | 2014 | 10 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 80 | 0.120 |
Why?
|
| Gestational Age | 1 | 2019 | 1161 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2015 | 135 | 0.110 |
Why?
|
| Biomarkers | 2 | 2022 | 3083 | 0.110 |
Why?
|
| Models, Molecular | 1 | 2018 | 1079 | 0.110 |
Why?
|
| Whole Body Imaging | 2 | 2012 | 29 | 0.110 |
Why?
|
| Fanconi Anemia | 1 | 2014 | 44 | 0.110 |
Why?
|
| Drug Compounding | 2 | 2011 | 36 | 0.110 |
Why?
|
| Isoenzymes | 1 | 2014 | 228 | 0.110 |
Why?
|
| Molecular Imaging | 2 | 2016 | 63 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2023 | 16263 | 0.110 |
Why?
|
| Drug Design | 2 | 2021 | 151 | 0.110 |
Why?
|
| Models, Economic | 1 | 2013 | 51 | 0.110 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 85 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1694 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2013 | 802 | 0.100 |
Why?
|
| Phosphatidylethanolamines | 1 | 2012 | 21 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2016 | 1002 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 752 | 0.100 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2007 | 50 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 418 | 0.100 |
Why?
|
| Triage | 1 | 2013 | 135 | 0.100 |
Why?
|
| Fetus | 1 | 2016 | 584 | 0.100 |
Why?
|
| Concanavalin A | 1 | 2012 | 16 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 192 | 0.100 |
Why?
|
| Administration, Intravenous | 1 | 2012 | 143 | 0.100 |
Why?
|
| Uterus | 1 | 2016 | 569 | 0.100 |
Why?
|
| Coordination Complexes | 1 | 2011 | 6 | 0.100 |
Why?
|
| Dextrans | 1 | 2012 | 45 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 290 | 0.100 |
Why?
|
| Cell Survival | 2 | 2012 | 812 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2012 | 94 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 118 | 0.090 |
Why?
|
| Equipment Design | 1 | 2013 | 598 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 329 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 240 | 0.090 |
Why?
|
| Myocardium | 1 | 2017 | 1020 | 0.090 |
Why?
|
| Biological Transport | 1 | 2012 | 355 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 28 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 505 | 0.090 |
Why?
|
| Mammography | 2 | 2009 | 113 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2012 | 262 | 0.090 |
Why?
|
| Immunocompetence | 1 | 2011 | 31 | 0.090 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 42 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 1291 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 291 | 0.090 |
Why?
|
| Residence Characteristics | 2 | 2023 | 278 | 0.090 |
Why?
|
| Cell Line | 2 | 2013 | 2756 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2013 | 759 | 0.080 |
Why?
|
| HeLa Cells | 1 | 2012 | 806 | 0.080 |
Why?
|
| Pandemics | 3 | 2022 | 1104 | 0.080 |
Why?
|
| Surface Properties | 1 | 2009 | 83 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 452 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2012 | 460 | 0.080 |
Why?
|
| Capillary Permeability | 1 | 2009 | 76 | 0.080 |
Why?
|
| Macrophages | 1 | 2013 | 621 | 0.080 |
Why?
|
| Comorbidity | 1 | 2013 | 1530 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 521 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 1143 | 0.070 |
Why?
|
| Folate Receptors, GPI-Anchored | 2 | 2005 | 54 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 350 | 0.070 |
Why?
|
| Autophagy | 1 | 2011 | 393 | 0.070 |
Why?
|
| Technology, Pharmaceutical | 1 | 2007 | 20 | 0.070 |
Why?
|
| Capsules | 1 | 2007 | 21 | 0.070 |
Why?
|
| Risk Factors | 1 | 2021 | 10249 | 0.070 |
Why?
|
| Hippocampus | 1 | 2012 | 824 | 0.070 |
Why?
|
| Prevalence | 1 | 2013 | 2446 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 144 | 0.070 |
Why?
|
| Spine | 1 | 2007 | 142 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 119 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 206 | 0.060 |
Why?
|
| Urethane | 1 | 2004 | 5 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3561 | 0.060 |
Why?
|
| Photons | 1 | 2025 | 48 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 177 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2013 | 3444 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 265 | 0.060 |
Why?
|
| Respiratory Transport | 1 | 2003 | 2 | 0.050 |
Why?
|
| Bronchography | 1 | 2003 | 4 | 0.050 |
Why?
|
| Drug Stability | 1 | 2003 | 57 | 0.050 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2003 | 17 | 0.050 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 28 | 0.050 |
Why?
|
| Pulmonary Ventilation | 1 | 2003 | 28 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1775 | 0.050 |
Why?
|
| Radiography, Abdominal | 1 | 2003 | 47 | 0.050 |
Why?
|
| Adolescent | 4 | 2022 | 19221 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 66 | 0.050 |
Why?
|
| Cadaver | 1 | 2003 | 132 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2885 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 304 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2006 | 1136 | 0.050 |
Why?
|
| Protein Aggregates | 1 | 2021 | 28 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2023 | 262 | 0.050 |
Why?
|
| Aged | 2 | 2024 | 19830 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 158 | 0.050 |
Why?
|
| Mutation | 1 | 2015 | 5845 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 75 | 0.050 |
Why?
|
| Radiometry | 1 | 2021 | 38 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 34 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 282 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 297 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 93 | 0.040 |
Why?
|
| Protein Folding | 1 | 2021 | 216 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2021 | 55 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 87 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 234 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2021 | 63 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 181 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 1215 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 165 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 883 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 391 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 89 | 0.040 |
Why?
|
| Blood Volume | 1 | 2019 | 81 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 212 | 0.040 |
Why?
|
| Body Composition | 1 | 2022 | 522 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 553 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 251 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 490 | 0.040 |
Why?
|
| Logistic Models | 1 | 2023 | 1807 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 330 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 852 | 0.040 |
Why?
|
| Middle Aged | 2 | 2014 | 26884 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 538 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 1997 | 24 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1997 | 51 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 938 | 0.030 |
Why?
|
| Polyesters | 1 | 2017 | 39 | 0.030 |
Why?
|
| Meglumine | 1 | 2016 | 14 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2020 | 780 | 0.030 |
Why?
|
| Critical Care | 1 | 2022 | 655 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 58 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 81 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2022 | 1562 | 0.030 |
Why?
|
| United States | 2 | 2021 | 10866 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 947 | 0.030 |
Why?
|
| Cell Death | 2 | 2008 | 242 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 26 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 41 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 722 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1625 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 209 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 291 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2011 | 3055 | 0.020 |
Why?
|
| Hydrodynamics | 1 | 2011 | 25 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 41 | 0.020 |
Why?
|
| Amides | 1 | 2011 | 89 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 549 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 54 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2011 | 26 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 427 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 1032 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 94 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 132 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 152 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2009 | 22 | 0.020 |
Why?
|
| X-Rays | 1 | 2009 | 26 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 63 | 0.020 |
Why?
|
| Proteins | 1 | 2014 | 1036 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 205 | 0.020 |
Why?
|
| Phospholipids | 1 | 2009 | 106 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 95 | 0.020 |
Why?
|
| Carcinoma | 1 | 2011 | 287 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 686 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2009 | 139 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 867 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 722 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 32 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2011 | 526 | 0.020 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2007 | 8 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 778 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1873 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1892 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 410 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2007 | 26 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1021 | 0.020 |
Why?
|
| Blood | 1 | 2007 | 103 | 0.020 |
Why?
|
| KB Cells | 1 | 2006 | 5 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 96 | 0.020 |
Why?
|
| Veins | 1 | 2007 | 107 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2006 | 108 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 103 | 0.020 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 44 | 0.020 |
Why?
|
| Artifacts | 1 | 2007 | 109 | 0.020 |
Why?
|
| Arteries | 1 | 2007 | 224 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 1504 | 0.010 |
Why?
|
| Glioma | 1 | 2009 | 491 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1802 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2303 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2003 | 131 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 442 | 0.010 |
Why?
|
| Computational Biology | 1 | 2007 | 810 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 4258 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 12364 | 0.010 |
Why?
|
| Prognosis | 1 | 2008 | 4620 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2509 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 4534 | 0.010 |
Why?
|
| Culture Media | 1 | 1997 | 182 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 210 | 0.010 |
Why?
|
| Perfusion | 1 | 1997 | 207 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 822 | 0.010 |
Why?
|